A Phase 1, Randomized, Double-blind, Placebo-controlled, Single and Multiple-dose Escalation Study Evaluating the Safety, Pharmacokinetics, and Pharmacodynamics of VX-993 in Healthy Adults
Latest Information Update: 16 Oct 2023
At a glance
- Drugs VX 993 (Primary)
- Indications Pain
- Focus Adverse reactions
- Sponsors Vertex Pharmaceuticals
Most Recent Events
- 11 Oct 2023 Status changed from active, no longer recruiting to completed.
- 13 Sep 2023 Status changed from recruiting to active, no longer recruiting.
- 06 Jan 2023 Status changed from not yet recruiting to recruiting.